EP 062:31

BPC-157: what the evidence actually says

Name: BPC-157: what the evidence actually says
Uploaded: 2026-09-28
Duration: 2 min 31 s
Description: Promising in rats, unproven in people: the animal studies, the handful of human reports, where regulators stand, and why the vial is the biggest practical risk.

Promising in rats, unproven in people: the animal studies, the handful of human reports, where regulators stand, and why the vial is the biggest practical risk.

Transcript and sources

BPC-157 is one of the most hyped peptides online, sold as a 'Wolverine' compound that heals almost anything. So what does the evidence actually say?
It's a lab-made chain of fifteen amino acids, first described by researchers in Zagreb, Croatia, in the early 1990s.
They said it was the working piece of a larger protein found in stomach juice, and named it 'body protection compound.'
In rats, the results look impressive: faster healing of cut tendons, torn ligaments and injured muscle, and protection for the stomach and gut.
But look closer. Of about two hundred and thirty-five papers, roughly three quarters list the same lead researcher, and independent labs have rarely repeated the work.
When an independent team tested it on rat Achilles tendons in 2026, it found no significant benefit.
How might it work? Lab studies suggest it helps grow new blood vessels and helps tendon cells move, but no one has identified the receptor it acts on.
In people, the evidence is thin. Across five studies, only about eighty people have ever received it.
The one controlled trial testing whether it works, in ulcerative colitis, found no significant difference from placebo, and it was never published in full.
The newer reports are tiny, from one clinician, with no placebo group: sixteen people with knee pain, twelve with bladder pain, and two given it through an IV.
Proper placebo-controlled trials are only now starting, including one for hamstring injuries.
It's not an approved medicine in the U.S. It's banned in sport at all times, and in Australia it's prescription-only.
In 2026, FDA scientists advised against letting pharmacies compound it, citing missing safety data and possible immune reactions. A final decision is still pending.
For most people, the real risk is the vial. 'Research use only' products aren't checked before they're sold, and independent testing has found peptides that fail basic quality checks, some with bacterial toxins.
And the long-term questions are open. No one has studied it in people beyond two weeks, and because it grows blood vessels, some doctors worry about hidden tumors. That concern is theoretical.
Promising in rats. Unproven in people. Every study, with sources, is at peplexicon.com.

Sources